To better understand the potential clinical impact of ROCK1 protein expression in prostate cancer we took advantage of our large prognosis tissue microarray (TMA) with its attached database on clinical, pathological and molecular data and studied patterns of ROCK1 expression in more than 12 000 prostate cancer patients by immunohistochemistry. The gene discussed is ROCK1; the disease is Familial prostate cancer.